Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06298890
Other study ID # SASKAT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 2024
Est. completion date September 2027

Study information

Verified date March 2024
Source Lithuanian University of Health Sciences
Contact Reda Zemaitiene
Phone +37037327064
Email reda.zemaitiene@lsmuni.lt
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 2027
Est. primary completion date May 2026
Accepts healthy volunteers No
Gender All
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria: - Cataract patients from 50 to 90 years old who underwent uncomplicated phacoemulsification performed by one (and same) experienced surgeon. - Patients with no underlying ocular surface diseases (keratitis, keratoconjunctivitis and others). - Patients who previously did not undergo any ophthalmic surgery. Exclusion Criteria: - Patient expressed his wish to not participate in the study or discontinue it when already enrolled. - Severe dry eye disease diagnosed with OSDI/DEQ-5 and at least one of the following tests: TBUT less than 10 seconds, tear osmolarity higher than 308 mOsm/l or positive corneal staining. - Glaucoma. - Diabetes mellitus. - Systemic connective tissue disease, autoimmune disease. - Neurologic conditions including stroke, Bell's palsy, Parkinson's, trigeminal nerve dysfunction. - Patients who underwent refractive surgery (LASIK or PRK). - Contact lens users. - One or more of the following concomitant medications: psychiatric medicines, antihistamines and/or hormonal replacement. - Patients who are already regularly using topical drops or ointments.

Study Design


Intervention

Device:
Artificial tears (sodium hyaluronate 0.2%)
Patients randomised into Ist study group will use artificial tears 7 days before the cataract surgery 4 times a day and they will continue to use them after surgery for 3 months.

Locations

Country Name City State
Lithuania Lithuanian University of Health Sciences Kaunas

Sponsors (2)

Lead Sponsor Collaborator
Lithuanian University of Health Sciences Santen Oy

Country where clinical trial is conducted

Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of ocular surface changes following cataract surgery Measured using LacryDiag (Quantel Medical, France), parameters included: non-invasive tear break up time, the height of the tear meniscus, interferometry. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Primary Evaluation of the cornea morphology Evaluated performing confocal corneal microscopy, parameters include: corneal nerve fibre number and density. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Primary Evaluation of matrix metalloproteinase-9 (MMP-9) levels in patients' tears Matrix metalloproteinase 9 is an inflammatory biomarker that has been shown to be elevated in the tears of dry eye disease (DED) patients. MMP-9 testing is a valuable diagnostic tool in identifying the presence of ocular surface inflammation in DED patients. MMP-9 level results are classified as positive or negative. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Primary Evaluation of tear osmolarity Evaluated with the TearLab Osmolarity System. Increased osmolarity indicates dry eye. Values greater than 300 mOsm/kg are suggestive of dry eye. From 300 mOsm/L to 320 mOsm/L, is graded as mild; from 320 mOsm/L to 340 mOsm/L, is graded as moderate; and greater than 340 mOsm/L, is graded as severe. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Primary Evaluation of tear cytokine levels Interleukin -2, -6, -1ß, tumour necrosis factor a (TNFa), interferon-gamma (IFN-?) levels in tears are significantly higher in patients' with dry eye disease (DED) and they correlate with the severity of DED. Cytokine levels in tears will be evaluated using Human Immunotherapy Luminex® Performance Assay 25-plex Fixed Panel System. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Primary Assessment of central corneal sensitivity Measured using Cochet-Bonnet aesthesiometer (Luneau; Pruneay-Le-Gillon, France). 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Secondary Evaluation of potential pain biomarkers in patients' saliva Pain biomarkers which will be evaluated - soluble tumor necrosis factor-a receptor II (sTNFaRII), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), secretory IgA (SIgA). Pain is a common complaint in both dry eye disease (DED) and post-cataract surgery.
Pain biomarkers will be evaluated using ELISA methods.
7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Secondary Dry Eye Questionnaire-5 (DEQ5) 5-item The DEQ-5 consists of five questions that assess the following: frequency of watery eye, discomfort, and dryness (scored on a 0-4 scale) and late day discomfort and dryness intensity (scored on a 0 -5 scale). 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Secondary Ocular surface disease index (OSDI) OSDI is a 12-item questionnaire that assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Secondary Visual function (VFQ-25) questionnaire The 25-item questionnaire has several subscale categories that assesses different aspects of health-related quality of life including overall health, overall vision, difficulty with near vision, difficulty with distance vision, limitations in social functioning due to vision, role limitations due to vision, dependency on others due to vision, mental health symptoms due to vision, future expectations for vision, driving difficulties, and pain and discomfort around the eyes 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
Secondary Visual acuity evaluation (LogMAR) Mean change from baseline. 7 days preoperative, 1 week, 1, 3, 6,12 months postoperative.
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A